NEKTAR THERAPEUTICS |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.29 USD | -0.77% |
|
+13.16% | +128.32% |
| Jul. 01 | Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Comp Value Index | CI |
| Jul. 01 | Nektar Therapeutics(NasdaqCM:NKTR) added to Russell Small Cap Completeness Index | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,797 | 3,050 | 2,493 | 424.8 | 107.8 | 237.4 | - | - |
| Enterprise Value (EV) 1 | 3,951 | 1,988 | 1,759 | -80.2 | 72.51 | 149 | 21.46 | 20.46 |
| P/E ratio | -8.57 x | -6.83 x | -4.72 x | -1.15 x | -0.39 x | -1.59 x | -1.86 x | -2.06 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 33.1 x | 19.9 x | 24.5 x | 4.61 x | 1.2 x | 3.2 x | 3.57 x | 3.52 x |
| EV / Revenue | 34.5 x | 13 x | 17.3 x | -0.87 x | 0.8 x | 2.01 x | 0.32 x | 0.3 x |
| EV / EBITDA | -9.25 x | -4.84 x | -4.07 x | 0.22 x | -0.28 x | -1.1 x | -0.15 x | -0.13 x |
| EV / FCF | -11.1 x | -6.2 x | -4.11 x | 0.26 x | -0.37 x | -0.96 x | -0.12 x | -0.27 x |
| FCF Yield | -8.99% | -16.1% | -24.3% | 386% | -267% | -104% | -829% | -367% |
| Price to Book | 2.71 x | 2.84 x | 3.69 x | 1.16 x | 0.83 x | 13.1 x | 5.77 x | 8.14 x |
| Nbr of stocks (in thousands) | 175,922 | 179,399 | 184,557 | 187,954 | 190,771 | 184,020 | - | - |
| Reference price 2 | 21.58 | 17.00 | 13.51 | 2.260 | 0.5650 | 1.290 | 1.290 | 1.290 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/28/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 114.6 | 152.9 | 101.9 | 92.06 | 90.12 | 74.17 | 66.42 | 67.46 |
| EBITDA 1 | -426.9 | -410.9 | -432.3 | -363.1 | -255.9 | -135.3 | -144.6 | -153.3 |
| EBIT 1 | -440 | -425.1 | -446.4 | -376.2 | -263.7 | -151.4 | -163.5 | -170.8 |
| Operating Margin | -383.92% | -278% | -438.05% | -408.63% | -292.59% | -204.09% | -246.17% | -253.14% |
| Earnings before Tax (EBT) 1 | -440.1 | -443.9 | -523.3 | -365 | -276.3 | -155.6 | -174.7 | -184.1 |
| Net income 1 | -440.7 | -444.4 | -523.8 | -368.2 | -276.1 | -155.6 | -174.7 | -184.1 |
| Net margin | -384.47% | -290.65% | -514.03% | -399.98% | -306.31% | -209.78% | -263.09% | -272.83% |
| EPS 2 | -2.520 | -2.490 | -2.860 | -1.970 | -1.450 | -0.8091 | -0.6943 | -0.6250 |
| Free Cash Flow 1 | -355 | -320.5 | -427.6 | -309.7 | -193.5 | -155 | -178 | -75 |
| FCF margin | -309.7% | -209.62% | -419.65% | -336.41% | -214.67% | -208.99% | -268% | -111.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/28/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 25.01 | 24.82 | 21.58 | 23.62 | 22.02 | 21.59 | 20.5 | 24.14 | 23.88 | 21.64 | 17.54 | 17.74 | 17.38 |
| EBITDA 1 | -109.5 | -112.8 | -149.4 | -51.62 | -49.29 | -42.71 | - | - | -31.86 | - | -34 | -34 | -36 |
| EBIT 1 | -112.9 | -116.6 | -152.8 | -54.3 | -52.47 | -45.01 | -50.6 | -44.86 | -33.51 | -35.43 | -37.93 | -38.41 | -40.03 |
| Operating Margin | -451.48% | -469.58% | -708.07% | -229.85% | -238.25% | -208.44% | -246.84% | -185.82% | -140.3% | -163.72% | -216.21% | -216.44% | -230.32% |
| Earnings before Tax (EBT) 1 | -145.6 | -90.27 | -159 | -59.2 | -56.54 | -137.1 | -51.17 | -45.9 | -42.11 | -36.84 | -40.42 | -42.07 | -43.03 |
| Net income 1 | -145.6 | -90.39 | -159.1 | -59.05 | -59.69 | -137 | -51.12 | -45.84 | -42.08 | -36.8 | -40.42 | -42.07 | -43.03 |
| Net margin | -582.37% | -364.16% | -736.94% | -249.94% | -271.03% | -634.52% | -249.39% | -189.85% | -176.17% | -170.07% | -230.4% | -237.09% | -247.58% |
| EPS 2 | -0.7900 | -0.4900 | -0.8500 | -0.3100 | -0.3200 | -0.7300 | -0.2700 | -0.2400 | -0.2200 | -0.1900 | -0.2042 | -0.2093 | -0.2189 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/5/22 | 8/4/22 | 11/3/22 | 2/28/23 | 5/9/23 | 8/8/23 | 11/7/23 | 3/4/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 153 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 1,062 | 734 | 505 | 35.3 | 88.4 | 216 | 217 |
| Leverage (Debt/EBITDA) | -0.359 x | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -355 | -321 | -428 | -310 | -193 | -155 | -178 | -75 |
| ROE (net income / shareholders' equity) | -28.2% | -35.8% | -59.6% | -70.4% | -111% | -210% | -312% | -195% |
| ROA (Net income/ Total Assets) | -21.4% | -25.3% | -39.4% | -40.3% | -49.8% | -46% | -53% | -48.5% |
| Assets 1 | 2,064 | 1,758 | 1,328 | 913.9 | 554.3 | 338.4 | 329.4 | 379.8 |
| Book Value Per Share 2 | 7.960 | 5.980 | 3.660 | 1.940 | 0.6800 | 0.1000 | 0.2200 | 0.1600 |
| Cash Flow per Share | - | - | -2.250 | -1.620 | - | - | - | - |
| Capex 1 | 26.3 | 7.26 | 15 | 5.68 | 0.86 | 10 | 2 | - |
| Capex / Sales | 22.93% | 4.75% | 14.71% | 6.17% | 0.95% | 13.48% | 3.01% | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/28/23 | 3/4/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
1.29
USD
Average target price
1.6
USD
Spread / Average Target
+24.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +128.32% | 239M | |
| +56.89% | 809B | |
| +39.52% | 624B | |
| -6.55% | 351B | |
| +7.92% | 289B | |
| +13.74% | 240B | |
| +13.83% | 220B | |
| -0.49% | 219B | |
| +7.94% | 166B | |
| -2.57% | 157B |
- Stock Market
- Equities
- NKTR Stock
- Financials Nektar Therapeutics
